Caroline serves as SVP Asset & Portfolio Leadership for Mariana Oncology. She brings 15+ years of experience in oncology drug development, with a proven track record of preclinical, translational and clinical development from candidate nomination through approval. Before joining Mariana, Caroline was SVP, Global Disease Area Lead at SpringWorks Therapeutics (NASDAQ: SWTX) where she worked on OGSIVEO™, a targeted therapy recently approved for the treatment of desmoid tumors and in development for multiple myeloma and ovarian granulosa cell tumors.
She previously served as VP, R&D Programs and Strategy at Turnstone Biologics (NASDAQ: TSBX), having joined as the first full-time employee and responsible for cross-functional leadership of oncolytic immunotherapy and autologous cell therapy programs. Prior to Turnstone, Caroline was VP, Clinical & Translational Research at SillaJen Biotherapeutics (formerly Jennerex Biotherapeutics), where she designed and executed preclinical and clinical studies to elucidate mechanism of action of oncolytic immunotherapies, leading to publications in Nature, Nature Medicine and Science Translational Medicine.
Caroline received her PhD in biochemistry, microbiology and immunology from the University of Ottawa and Honors Degree from McGill University.